Erectile Dysfunction - Pipeline Review, H2 2016

Published: Jul, 2016 | Pages: 108 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Erectile Dysfunction - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Erectile Dysfunction - Pipeline Review, H2 2016', provides an overview of the Erectile Dysfunction pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Erectile Dysfunction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Erectile Dysfunction and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Erectile Dysfunction
- The report reviews pipeline therapeutics for Erectile Dysfunction by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Erectile Dysfunction therapeutics and enlists all their major and minor projects
- The report assesses Erectile Dysfunction therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Erectile Dysfunction

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Erectile Dysfunction
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding  Erectile Dysfunction pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Erectile Dysfunction Overview 10
Therapeutics Development 11
Pipeline Products for Erectile Dysfunction - Overview 11
Pipeline Products for Erectile Dysfunction - Comparative Analysis 12
Erectile Dysfunction - Therapeutics under Development by Companies 13
Erectile Dysfunction - Therapeutics under Investigation by Universities/Institutes 15
Erectile Dysfunction - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Unknown Stage Products 19
Erectile Dysfunction - Products under Development by Companies 20
Erectile Dysfunction - Products under Investigation by Universities/Institutes 22
Erectile Dysfunction - Companies Involved in Therapeutics Development 23
Apricus Biosciences, Inc. 23
Aytu BioScience, Inc. 24
Biopharm GmbH 25
Futura Medical Plc 26
Hanmi Pharmaceuticals, Co. Ltd. 27
Humanetics Corporation 28
IntelGenx Corp. 29
Ion Channel Innovations, LLC 30
Mezzion Pharma Co. Ltd. 31
Mitsubishi Tanabe Pharma Corporation 32
Monosol Rx, LLC 33
NAL Pharmaceuticals Ltd. 34
Palatin Technologies, Inc. 35
Pharmicell Co., Ltd. 36
Sihuan Pharmaceutical Holdings Group Ltd. 37
Suda Ltd 38
Yungjin Pharm. Co., Ltd. 39
Erectile Dysfunction - Therapeutics Assessment 40
Assessment by Monotherapy Products 40
Assessment by Combination Products 41
Assessment by Target 42
Assessment by Mechanism of Action 44
Assessment by Route of Administration 46
Assessment by Molecule Type 48
Drug Profiles 50
(PDE-5 Inhibitor + tramadol hydrochloride) - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
alprostadil - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
AP-102 - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
avanafil - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
BIO-300 - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
BL-214 - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
Cellgram-ED - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
fadanafil - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
HCP-1302 - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
HCP-1303 - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
MED-2002 - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
MED-2005 - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
Peptide to Activate G Protein-Coupled Receptor Mas for Cardiovascular, Metabolic Disorders and Erectile Dysfunction - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
pVAX-hSlo - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
Recombinant Protein for Bone Fracture, Degenerative Disc Disease, Erectile Dysfunction and Parkinson's Disease - Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
sildenafil citrate - Drug Profile 74
Product Description 74
Mechanism Of Action 74
R&D Progress 74
sildenafil citrate - Drug Profile 75
Product Description 75
Mechanism Of Action 75
R&D Progress 75
sildenafil citrate - Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
Small Molecule to Inhibit PDE5 for Erectile Dysfunction - Drug Profile 77
Product Description 77
Mechanism Of Action 77
R&D Progress 77
SUD-003 - Drug Profile 78
Product Description 78
Mechanism Of Action 78
R&D Progress 78
Synthetic Peptide to Agonize Melanocortin 4 Receptor for Female Sexual Dysfunction and Erectile Dysfunction - Drug Profile 80
Product Description 80
Mechanism Of Action 80
R&D Progress 80
T-6932 - Drug Profile 81
Product Description 81
Mechanism Of Action 81
R&D Progress 81
tadalafil - Drug Profile 82
Product Description 82
Mechanism Of Action 82
R&D Progress 82
tadalafil - Drug Profile 83
Product Description 83
Mechanism Of Action 83
R&D Progress 83
tadalafil - Drug Profile 84
Product Description 84
Mechanism Of Action 84
R&D Progress 84
TF-0092 - Drug Profile 85
Product Description 85
Mechanism Of Action 85
R&D Progress 85
TPN-729 - Drug Profile 86
Product Description 86
Mechanism Of Action 86
R&D Progress 86
TR-399 - Drug Profile 87
Product Description 87
Mechanism Of Action 87
R&D Progress 87
udenafil - Drug Profile 88
Product Description 88
Mechanism Of Action 88
R&D Progress 88
VLFIA-330 - Drug Profile 91
Product Description 91
Mechanism Of Action 91
R&D Progress 91
YBH-1603 - Drug Profile 92
Product Description 92
Mechanism Of Action 92
R&D Progress 92
Erectile Dysfunction - Dormant Projects 93
Erectile Dysfunction - Discontinued Products 97
Erectile Dysfunction - Product Development Milestones 98
Featured News & Press Releases 98
Mar 28, 2016: MonoSol Rx Successfully Completes Pre-IND Meeting with the FDA for PharmFilm Tadalafil 98
Nov 25, 2015: iX Biopharma Announces Success Of Pilot Bioavailability Study For Pheonix 98
Jan 29, 2015: VIVUS Announces European Approval of SPEDRA Label Amendment; SPEDRA Now First and Only Oral Erectile Dysfunction Treatment Approved in Europe to Be Taken Approximately 15 Minutes Before Sexual Activity 99
Nov 20, 2014: Auxilium Pharmaceuticals Presents STENDRA Data At SMSNA Scientific Meeting 99
Nov 03, 2014: Auxilium Pharmaceuticals To Present STENDRA Data At SMSNA Scientific Meeting 100
Sep 18, 2014: VIVUS and Auxilium Announce FDA Approval of STENDRA sNDA; STENDRA Now First and Only Oral Erectile Dysfunction Treatment Approved to Be Taken Approximately 15 Minutes Before Sexual Activity 100
Jul 09, 2014: New Grant Enables Humanetics to Evaluate Potential Treatment for Erectile Dysfunction in Prostate Cancer Patients 101
Apr 11, 2014: VIVUS To Present Clinical Data On Avanafil at European Association of Urology 102
Feb 24, 2014: IntelGenx Achieves Positive Bioequivalence Results for Erectile Dysfunction VersaFilm Tadalafil Product 102
Jan 21, 2014: VIVUS and Auxilium Announce FDA Acceptance of Supplemental Filing Seeking an Update of Prescribing Information for STENDRA (avanafil) 102
Aug 01, 2013: VIVUS Announces Commercial Supply Agreement With Sanofi to Produce Avanafil 103
Jun 26, 2013: Vivus Announces European Approval For Spedra For Treatment Of Erectile Dysfunction 103
Jun 19, 2013: Vivus Announces Positive Results From TA-501 Clinical Trial Of Stendra For Treatment Of Men With Erectile Dysfunction 105
Apr 25, 2013: Vivus Receives CHMP Positive Opinion For Spedra For Treatment Of Erectile Dysfunction In Adult Men 106
Jul 18, 2012: Zydus Urosciences Launches Udenafil For Treatment Of Erectile Dysfunction In India 106
Appendix 107
Methodology 107
Coverage 107
Secondary Research 107
Primary Research 107
Expert Panel Validation 107
Contact Us 107
Disclaimer 108

List of Tables

Number of Products under Development for Erectile Dysfunction, H2 2016 11
Number of Products under Development for Erectile Dysfunction - Comparative Analysis, H2 2016 12
Number of Products under Development by Companies, H2 2016 14
Number of Products under Investigation by Universities/Institutes, H2 2016 15
Comparative Analysis by Late Stage Development, H2 2016 16
Comparative Analysis by Clinical Stage Development, H2 2016 17
Comparative Analysis by Early Stage Development, H2 2016 18
Comparative Analysis by Unknown Stage Development, H2 2016 19
Products under Development by Companies, H2 2016 20
Products under Development by Companies, H2 2016 (Contd..1) 21
Products under Investigation by Universities/Institutes, H2 2016 22
Erectile Dysfunction - Pipeline by Apricus Biosciences, Inc., H2 2016 23
Erectile Dysfunction - Pipeline by Aytu BioScience, Inc., H2 2016 24
Erectile Dysfunction - Pipeline by Biopharm GmbH, H2 2016 25
Erectile Dysfunction - Pipeline by Futura Medical Plc, H2 2016 26
Erectile Dysfunction - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2016 27
Erectile Dysfunction - Pipeline by Humanetics Corporation, H2 2016 28
Erectile Dysfunction - Pipeline by IntelGenx Corp., H2 2016 29
Erectile Dysfunction - Pipeline by Ion Channel Innovations, LLC, H2 2016 30
Erectile Dysfunction - Pipeline by Mezzion Pharma Co. Ltd., H2 2016 31
Erectile Dysfunction - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2016 32
Erectile Dysfunction - Pipeline by Monosol Rx, LLC, H2 2016 33
Erectile Dysfunction - Pipeline by NAL Pharmaceuticals Ltd., H2 2016 34
Erectile Dysfunction - Pipeline by Palatin Technologies, Inc., H2 2016 35
Erectile Dysfunction - Pipeline by Pharmicell Co., Ltd., H2 2016 36
Erectile Dysfunction - Pipeline by Sihuan Pharmaceutical Holdings Group Ltd., H2 2016 37
Erectile Dysfunction - Pipeline by Suda Ltd, H2 2016 38
Erectile Dysfunction - Pipeline by Yungjin Pharm. Co., Ltd., H2 2016 39
Assessment by Monotherapy Products, H2 2016 40
Assessment by Combination Products, H2 2016 41
Number of Products by Stage and Target, H2 2016 43
Number of Products by Stage and Mechanism of Action, H2 2016 45
Number of Products by Stage and Route of Administration, H2 2016 47
Number of Products by Stage and Molecule Type, H2 2016 49
Erectile Dysfunction - Dormant Projects, H2 2016 93
Erectile Dysfunction - Dormant Projects (Contd..1), H2 2016 94
Erectile Dysfunction - Dormant Projects (Contd..2), H2 2016 95
Erectile Dysfunction - Dormant Projects (Contd..3), H2 2016 96
Erectile Dysfunction - Discontinued Products, H2 2016 97